@lungcancereurope.bsky.social‼️ Our 12th Annual Report Survey closes this Wednesday, 14 October.
Thank you to everyone who has already shared their experience.
If you’re living with #lungcancer or caring for someone who is and haven’t taken part yet, there’s still time:
es.surveymonkey.com/r/LungCancer...
@lungcancereurope.bsky.socialBelgium has announced a 🆕 10-yr cancer plan, inclu plans to concentrate complex #lungcancer care in specialist centres from 2028.
The plan also includes a national expert panel to support difficult trtmt decisions.
The challenge now is turning these commitments into better, accessible care. #LCSM
@alkpositiveuk.bsky.socialA huge thank you to Stephen, who swam 2 miles at Swim Serpentine to raise funds for ALK Positive #LungCancer UK! 💙
Stephen joined 4,600 swimmers in London’s Hyde Park, completing his swim in 1 hour 34 minutes.
Well done, Stephen, and thank you for supporting our ALK+ lung cancer community! 👏 #LCSM
@lungcancereurope.bsky.socialGood news for #lungcancer screening in Europe.
Poland is launching a nationally funded lung cancer screening programme this Oct, offering free low-dose CT scans to people at higher risk.
Access to early detection still varies widely across Europe. This is an important step forward. #LCSM
@allyouneedislungs.bsky.socialHow can we spot #lungcancer earlier in people who have never smoked?
A new review found 31 existing prediction models, but none met all quality standards.
More research is needed to help identify who may be at risk.
@lungcancereurope.bsky.socialAround 1,700 #lungcancer cases could be prevented across the EU over the next 40 years under stronger workplace protections, according to the European Commission.
The European Parliament backed the new rules this week.
@allyouneedislungs.bsky.socialWhy do people who have never smoked develop #lungcancer?
The UK’s OLIVE study is looking at who is affected, how lung cancer is diagnosed and outcomes, with the aim of improving diagnosis and care. #LCSM
@onclive.bsky.socialDid you miss any of September's pivotal @fda.gov oncology approvals? Catch up here with the data and significance of each decision #bcsm #lcsm #oncology
Read more: www.onclive.com/view/septemb...
@lungcancereurope.bsky.social🆕 research looks at what may happen before some smoking-related lung cancers develop.
Long-term cigarette smoke exposure changed lung stem cells in a lab model, with KRAS linked to adenocarcinoma and TP53 loss to squamous cell carcinoma. #LCSM #lungcancer
@onclive.bsky.social🫁 The @fda.gov has granted breakthrough therapy designation to telisotuzumab adizutecan monotherapy for previously treated, c-Met–expressing, EGFR wild-type nonsquamous NSCLC. #lcsm #oncology
Full story ➡️: www.onclive.com/view/fda-gra...
@alkpositiveuk.bsky.socialOur first 2026 ALK+ #luncancer UK member survey report is out.
180 people took part - 18 were caregivers.
82% of people with ALK+ were diagnosed at stage 4, 67% had never/minimally smoked, and 1/2 had caring responsibilities.
Read the demographics report: tr.ee/jAki-M0aYK
@lungcancereurope.bsky.social#Lungcancer screening is also a chance to offer help with 🚭 .
A US trial of 3.2K people referred for screening, 8.8% offered medication & financial incentives had verified abstinence at 6 mths, Vs 4.3% given usual support.
Practical help, without judgement.
@onclive.bsky.social🫁 Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in the FURVENT trial. #lcsm #oncology
Full story ➡️: www.onclive.com/view/firmone...
@fumikochino.bsky.social💸🏥🩺 Medical debt is a scourge. In addition to the deep personal and economic harms it perpetuates on Americans, new data @jamanetworkopen.com @jama.com shows that it may ALSO drive incidence of late-stage cancer diagnoses with the worst outcomes in #lungcancer #lcsm
@eaonc.bsky.socialThe EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
@onclive.bsky.social🫁 Lung cancer experts discuss strategies after immunotherapy in advanced squamous NSCLC. @narjustflorezmd.bsky.social @christianrolfo.bsky.social @cityofhope.bsky.social @osucccjames.bsky.social @danafarber.bsky.social @iaslc.bsky.social #WCLC26 #lcsm #oncology
@lungcancereurope.bsky.socialIt’s the FINAL week for our 12th Annual Report Survey.
We’re gathering evidence on quality of life and support needs for people affected by #lungcancer across Europe.
Please take part if eligible, or share with patients, members and networks:
es.surveymonkey.com/r/LungCancer... #LCSM
@btog.bsky.social📅 Register now!
The 25th BTOG Annual Conference takes place 3–5 March 2026 at the EICC Edinburgh. Join the UK’s leading thoracic oncology community.
🔗 https://btog.org/25th-btog-annual-conference-2027
#LCSM
@lungcancereurope.bsky.socialA clear first scan doesn’t end the need for #lungcancer screening.
In BioMILD, 105 of 3,464 people who smoked heavily had a negative CT but were later diagnosed with lung cancer. Median follow-up: 9.4 years.
Screening needs follow-up. #LCSM
